



Ministry of Health 'Influenza A (H1N1) Treatment Proposal (2010 Version) '
Suggested using Arbidol Hydrochloride
A drug Developed and Researched by Lijun International Pharmaceutical (2005.hk)

(10 May 2010 – Hong Kong) Lijun International Pharmaceutical (Holding) Co., Ltd. ("Lijun International" or the "Company"; stock code: 2005) and its subsidiary (the "Group") are pleased to announce that Ministry of Health of PRC (Ministry of Health) recently distributed document 'Influenza A (H1N1) Treatment Proposal (2010 Version)' (甲型 H1N1 流感診療方案 (2010 年版)) to medical institutions for the diagnosis and treatment of Influenza A (H1N1). The document suggested using Arbidol Hydrochloride (鹽酸阿比朵爾), a drug developed and researched by the Company, for anti-viral treatment.

According to research, Influenza A (H1N1) virus is allergic to Neuraminidase Inhibitors (神經氨酸酶抑制劑) Oseltamivir (奧司他韋) and Zanamivir (札那米韋), and is resistant to Amantadine (金剛烷胺) and Rimantadine (金剛乙胺). Medical institutions could use Arbidol Hydrochloride and other medicines as well.

Mr Qu Jiguang, Director of Lijun International said, 'Enerxin Capsule (generic name: Arbidol Hydrochloride Capsule) is an antiviral drug developed and researched by the Company. It is announced by the Authority that Enerxin Capsule had an obvious function on the restraint of the growth of Influenza A (H1N1) in cells. The reviewed Proposal by the Ministry of Health indicated the effectiveness of the medicine, in which showed the recognition and support towards the Company's effort in the research and development.'

Mr Qu continued, 'With the growing recognition of Enerxin Capsule within mainland's medical industry, we expect the market of Capsule to be extensive. The Company will appropriately increase capacity of Capsule to meet the demand of the market, and will strive to maintain quality of products so as to provide safe drug treatment for citizens.'

- End -

About Lijun International Pharmaceutical (Holding) Co., Ltd.

As one of the leading manufacturers in the pharmaceutical industry in China, Lijun International Pharmaceutical (Holding) Co., Ltd. has more than 70-year operating history and well-known brands. The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005). The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product. The Group has manufacturing plants in Hebei Province and Shaanxi Province, the People's Republic of China and sells to customers mainly in Mainland China. The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market. The Company boasts of its robust brand strength including "Lijunsha", a "Famous Trademark" in China and one of the "Ten Favourite Trademarks" which took over approximately 66% market share in 2009. The Group successfully acquired Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a leading intravenous infusion solution manufacturer in China in June 2007 to expand its intravenous infusion solution production business. Facing more merger and acquisition opportunities from medical reform, the Group is positioned for continuous mergers and acquisitions to promote its growth.

This press release is issued by Wonderful Sky Financial Group Limited on behalf of Lijun International Pharmaceutical (Holding) Co., Ltd.

For media inquiries, please contact:

Wonderful Sky Financial Group Limited

Cherry Qiu / Daisy Sun / Sandra Ho / Olivia Davidson

Dir: (852) 3970 2185 / 3970 2183 / 3970 2132

Tel: (852) 2851 1038

Fax: (852) 2815 1352

E-mail: cherryqiu@wsfg.hk / daisysun@wsfg.hk / sandraho@wsfg.hk / oliviadavidson@wsfg.hk